| Autor: |
Miikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, Timo Marttila, Ray McDermott, Timo Joensuu, Ilari Lehtinen, Claes Ginman, Pirkko-Liisa Kellokumpu-Lehtinen |
| Přispěvatelé: |
Tampere University, Clinical Medicine, Health Sciences, Tays Research Services, Seinäjoen keskussairaala VA, TAYS Cancer Centre |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Popis: |
Introduction: Treatment with 2-weekly docetaxel 50 mg/m2 was shown to improve overall survival and was better tolerated than the standard 75 mg/m2 3-weekly regimen in men with metastatic castration-resistant prostate cancer (mCRPC) in the original randomised PROSTY trial. The aim of this study was to investigate, whether quality of life (QoL) effects would differ between the 2-weekly docetaxel 50 mg/m2 regimen from the standard 3-weekly 75 mg/m2 treatment. Materials and Methods: QoL data were collected with the Functional Assessment of Cancer Therapy–Prostate (FACT-P) and Functional Assessment of Cancer Therapy Advanced Prostate Symptom Index − 8 Item version (FAPSI-8). Pain was measured using the Visual Analogue Scale (VAS). A total of 743 forms from 163 patients were analysed in Arm A (2-weekly docetaxel), and 704 forms from 173 patients were analysed in Arm B (3-weekly docetaxel). The data were analysed using both the Wilcoxon signed rank test (with Holm–Bonferroni adjustment) and Mann–Whitney U models. Results: No major differences were found in total QoL. Total QoL was higher at month 8 in Arm B (p =.020), but this was reversed in the following month (p =.043), and no statistically significant differences were found during other months. Compared to Arm A, participants in Arm B had longer-lasting deterioration in FAPSI-8 scores and emotional well-being subdomain at the beginning of treatment (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
